Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

NCT ID: NCT03433222

Last Updated: 2018-02-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-31
• Study Completion Date: 2019-01-08

Brief Summary

The goal of this study is to establish the safety of high fluence LED-RL at fluence of 480 J/cm2 and 640 J/cm2 in healthy non-Hispanic, Caucasian subjects. The hypothesis is that high fluence LED-RL phototherapy is safe in non-Hispanic, Caucasians.

Detailed Description

The effects of visible light, while common in the environment (visible spectrum accounts for 44% of total solar energy), remain undefined. An important safety feature of visible red light (600 nm to 700 nm) is that it does not generate pro-carcinogenic DNA damage as does ultraviolet (UV) light. Recently published clinical observations indicate that red light in combination with other modalities such as photosensitizers in combined red light photodynamic therapy can treat skin diseases. However, preliminary in vitro data generated by the investigator's research group suggests that red light can function as a stand-alone treatment, eliminating the side-effects of chemical photosensitizers and the potential long-term harm of current UV therapy. Furthermore, commercially available light emitting diode-red light (LED-RL) units exist and are already FDA-cleared for other dermatological uses (such as rhytides and acne), thus clinical translation for use in skin diseases could occur relatively quickly following safety and efficacy demonstration. Developing high fluence LED-RL phototherapy as a treatment for skin conditions may represent an important advance that lacks the serious systemic side effects associated with immunomodulatory agents (such as oral steroids); avoids the need for invasive, painful injections with anti-fibrotic agents (such as intralesional steroids, 5-fluorouracil and bleomycin); and eliminates the UV-induced DNA damage associated with skin cancer and photoaging that are associated with current UVA/UVA1 and UVB/narrowband UVB phototherapy. To the investigator research group's knowledge, no clinical trials have been performed to determine the safety of high fluence LED-RL in different Fitzpatrick skin types. The innovation of this approach is that the investigator research group intend to study the safety of high fluence LED-RL in Fitzpatrick skin types I to III (based on NIH's race/ethnicity category of non-Hispanic, Caucasian).

A previous study demonstrated that fluence up to 320 J/cm2 is safe for all skin types (unpublished data, investigator research group). This study will evaluate doses of 480 J/cm2 and 640 J/cm2 in Fitzpatrick skin types I to III. This is based on the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2 which is the maximum recommended starting dose in clinical studies, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2).

Conditions

Skin Diseases; Keloid; Scar; Fibrosis; Hypertrophic Skin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: SINGLE

Study Groups

HF-LED-RL Phototherapy

The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).

After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event.

Group Type: EXPERIMENTAL

HF-LED-RL Phototherapy

Intervention Type: DEVICE

The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.

All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.

Mock Therapy

The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).

After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event.

Group Type: SHAM_COMPARATOR

Mock Therapy

Intervention Type: DEVICE

Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.

All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.

Interventions

HF-LED-RL Phototherapy

The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.

All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.

Intervention Type: DEVICE

Mock Therapy

Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.

All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.

Intervention Type: DEVICE

Other Intervention Names

Omnilux New-U (Photo Therapeutics, Carlsbad, CA); Mock therapy unit (Photo Therapeutics, Carlsbad, CA)

Eligibility Criteria

Inclusion Criteria

• Healthy subjects of any sex and age
• Non-Hispanic, Caucasian race/ethnicity
• Nondominant proximal anterior forearm is wide enough to ensure reproducible placement of LED-RL phototherapy or mock therapy hand-held unit
• Available and willing to attend all clinic visits
• Able and willing to give informed consent

Exclusion Criteria

• Subjects using any photosensitizers (i.e. lithium, melatonin, phenothiazine antipsychotics, antibiotics)
• Subjects with diabetes mellitus (DM)
• Subjects with a history of skin cancer.
• Subjects with systemic lupus erythematous (SLE)
• Subjects with light-sensitive conditions (All subjects will be tested for photosensitivity per manufacturer user guide instructions)
• Subjects with open wounds on the nondominant proximal anterior forearm
• Subjects with fibrotic skin disease or other skin conditions on the nondominant proximal anterior forearm
• Subjects with tattoos that cover the procedure site on the nondominant proximal anterior forearm
• Subjects of an ethnic race group other than Non-Hispanic, Caucasian
• Subjects who have previously participated in the VA Northern California's "Phase 1 Study of LED-RL in Human Skin"

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

East Bay Institute for Research and Education

OTHER

Sponsor Role: collaborator

VA Northern California Health Care System

FED

Sponsor Role: lead

Responsible Party

Jared Jagdeo, MD, MS

Physician, Dermatology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jared Jagdeo, MD, MS

Role: PRINCIPAL_INVESTIGATOR

Physician, Dermatology

Locations

Sacramento VA Medical Center

Mather, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Jared Jagdeo, MD, MS

Role: CONTACT

Jared.Jagdeo@va.gov

916-451-7245

Facility Contacts

Jared Jagdeo, MD, MS

Role: primary

Jared.Jagdeo@va.gov

916-451-7245

Erica Wang, MD

Role: backup

Erica.Wang2@va.gov

References

Jagdeo JR, Adams LE, Brody NI, Siegel DM. Transcranial red and near infrared light transmission in a cadaveric model. PLoS One. 2012;7(10):e47460. doi: 10.1371/journal.pone.0047460. Epub 2012 Oct 15.

Reference Type: BACKGROUND

PMID: 23077622 (View on PubMed)

Mamalis A, Jagdeo J. Light-emitting diode-generated red light inhibits keloid fibroblast proliferation. Dermatol Surg. 2015 Jan;41(1):35-9. doi: 10.1097/01.DSS.0000452650.06765.51.

Reference Type: BACKGROUND

PMID: 25485805 (View on PubMed)

Sadick NS. A study to determine the efficacy of a novel handheld light-emitting diode device in the treatment of photoaged skin. J Cosmet Dermatol. 2008 Dec;7(4):263-7. doi: 10.1111/j.1473-2165.2008.00404.x.

Reference Type: BACKGROUND

PMID: 19146602 (View on PubMed)

Sadick NS. Handheld LED array device in the treatment of acne vulgaris. J Drugs Dermatol. 2008 Apr;7(4):347-50.

Reference Type: BACKGROUND

PMID: 18459515 (View on PubMed)

Lev-Tov H, Mamalis A, Brody N, Siegel D, Jagdeo J. Inhibition of fibroblast proliferation in vitro using red light-emitting diodes. Dermatol Surg. 2013 Aug;39(8):1167-70. doi: 10.1111/dsu.12212. Epub 2013 Apr 16.

Reference Type: BACKGROUND

PMID: 23590233 (View on PubMed)

Ho D, Kraeva E, Wun T, Isseroff RR, Jagdeo J. A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials. 2016 Aug 2;17:385. doi: 10.1186/s13063-016-1518-7.

Reference Type: BACKGROUND

PMID: 27484782 (View on PubMed)

Wang EB, Kaur R, Nguyen J, Ho D, Austin E, Maverakis E, Li CS, Hwang ST, Isseroff RR, Jagdeo J. A single-blind, dose-escalation, phase I study of high-fluence light-emitting diode-red light on Caucasian non-Hispanic skin: study protocol for a randomized controlled trial. Trials. 2019 Mar 20;20(1):177. doi: 10.1186/s13063-019-3278-7.

Reference Type: DERIVED

PMID: 30894210 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

18-01-00804

Identifier Type: -

Identifier Source: org_study_id